Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yoshida, T.
Right arrow Articles by Kuwano, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, T.
Right arrow Articles by Kuwano, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:252-256, 2004
© 2004 European Society for Medical Oncology

Original Paper

The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer

Received 28 March 2003; revised 22 October 2003; accepted 6 November 2003

Background:

Cyclin B1 has an important role in the G2–M phase transition of the cell cycle. Wee1 delays mitosis by suppressing the activity of the Cyclin B1/cdc2 complex. The objective of the present study was to elucidate the clinicopathological and prognostic significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer (NSCLC).

Patients and methods:

An immunohistochemical assessment of Cyclin B1 and Wee1 expression was performed in 79 patients with NSCLC.

Results:

The expression of Cyclin B1 was correlated with differentiation (P = 0.0423) and vascular invasion (P = 0.001). Patients with overexpression of Cyclin B1 had higher mean values for both the Ki-67 proliferative index (Ki-Index) (P <0.0001) and proliferating cell nuclear antigen labeling index (PCNA-LI) (P <0.0001), and a poorer prognosis (P = 0.0068). Patients lacking expression of Wee1 had a higher recurrence rate (P = 0.0084) and a poorer prognosis (P = 0.0457), and tended to have higher Ki-Index and PCNA-LI values. Multivariate analysis suggested that both Cyclin B1 (P = 0.0244) and Wee1 (P = 0.0444) expression were significant prognostic factors.

Conclusions:

These findings suggest that Cyclin B1 expression could be a significant prognostic parameter in NSCLC. The loss of Wee1 expression may have a potential role in promoting tumor progression and may be a significant prognostic indicator in NSCLC.

T. Yoshida*, S. Tanaka, A. Mogi, Y. Shitara and H. Kuwano

Department of Surgery I, Gunma University Faculty of Medicine, Gunma, Japan

Key words: cell cycle, Cyclin B1, differential PCR, immunohistochemistry, non-small-cell lung cancer, Wee1


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. Shen, C. Behrens, I. I. Wistuba, L. Feng, J. J. Lee, W. K. Hong, and R. Lotan
Identification and Validation of Differences in Protein Levels in Normal, Premalignant, and Malignant Lung Cells and Tissues Using High-Throughput Western Array and Immunohistochemistry
Cancer Res., December 1, 2006; 66(23): 11194 - 11206.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C-Q Zhu, W Shih, C-H Ling, and M-S Tsao
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.
J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
A. M. EGLOFF, J. WEISSFELD, S. R. LAND, and O. J. FINN
Evaluation of Anticyclin B1 Serum Antibody as a Diagnostic and Prognostic Biomarker for Lung Cancer
Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 29 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Chen, M. S. Bhojani, A. C. Heaford, D. C. Chang, B. Laxman, D. G. Thomas, L. B. Griffin, J. Yu, J. M. Coppola, T. J. Giordano, et al.
Phosphorylated FADD induces NF-{kappa}B, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas
PNAS, August 30, 2005; 102(35): 12507 - 12512.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
V Esposito, A Baldi, A De Luca, G Tonini, B Vincenzi, D Santini, P Persichetti, A Mancini, G Citro, F Baldi, et al.
Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer
J. Clin. Pathol., July 1, 2005; 58(7): 734 - 739.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda
Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review
Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. S. Aljada, N. Ramnath, K. Donohue, S. Harvey, J. J. Brooks, S. M. Wiseman, T. Khoury, G. Loewen, H. K. Slocum, T. M. Anderson, et al.
Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer
J. Clin. Oncol., August 15, 2004; 22(16): 3218 - 3229.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.